Document is current

Article History

Received: 1 November 2023

Accepted: 29 November 2023

First Online: 10 January 2024

Declarations

:

: Arun K Mankan, Begona de las Heras, Olga Bodriagova, Laura Vidal, and Kamal S. Saini are employed by Fortrea Inc. Shakti H. Ramkissoon is employed by Labcorp Drug Development Inc. Nagender Mankan is employed by Northwest Georgia Oncology Centers, Roswell, Georgia, USA. Enrique Grande works at MD Anderson Cancer Center Madrid, Madrid, Spain. All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Kamal S Saini reports consulting fees from the European Commission, and stock and/or other ownership interests in Fortrea Inc. and Quantum Health Analytics (UK) Ltd., outside the submitted work. Enrique Grande has provided consulting/advisory services for MSD, Pfizer, Ipsen, Roche, Bristol-Myers Squibb, has received honoraria from Pfizer, Bristol-Myers Squibb, Ipsen, Roche, Eisai, Eusa Pharma, MSD, Genzyme, Advanced Accelerator Applications, Novartis, Pierre Fabre, Lexicon, Celgene, Janssen-Cilag, Astellas Pharma, AstraZeneca, and Lilly, and has received travel/accommodations/expenses from Bristol-Myers Squibb, Roche/Genentech, Pfizer, Janssen-Cilag, and Ipsen and has received research funding from Roche, Pfizer, AstraZeneca, Ipsen, Molecular Templates, Lexicon, Astellas Pharma.

: This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.